President: Mark Shumbera
Mr. Shumbera is the President of AM Biotechnologies, LLC as well as AptaMed, Inc. He formerly led MEI Technologies, Inc. Commercial Development Division where he built and managed MEI IP assets. While at MEI, Mr. Shumbera was responsible for establishing and assisting three start-up companies. He received a BS in Electrical Engineering from Texas A&M University and an MBA from The University of Houston Clear Lake.

Director, Research and Development: Xianbin Yang, PhD
Dr. Yang is the Director of Research and Development for AM Biotechnologies. He specializes in nucleic acid chemistry and was the lead scientist in Dr. David Gorenstein’s laboratory at UTMB. Dr. Yang has unsurpassed technical knowledge of thioaptamers and their applications. He received his PhD in Bioorganic Chemistry from Polish Academy of Sciences, Lodz, Poland in 1998 and has over 44 publications in the field as well as 5 patents/patents pending.

Director, Product Development: Ross Durland, PhD
Dr. Durland is the Director of Product Development. He has extensive industry product development experience encompassing nine different human therapeutic products from pre-IND stage to Phase IIb clinical testing. Dr. Durland received his PhD in Molecular Biology from the University of California, San Diego in 1988 and has 26 publications and three patents/patents pending.

Manager, Business Development: Tim McGrath
Mr. McGrath is the Manager, Business Development for AM. As the former CEO of Xeotron he raised over $4M from corporate investors and managed the sale of Xeotron to Invitrogen. While President of Sigma-Genosys, sales grew from $2M to over $40M and he negotiated numerous licenses and marketing agreements. He managed the sale of Genosys to Sigma-Aldrich. Mr. McGrath has a B.S. in Zoology and an M.S. in Biochemistry from Texas A&M University.